MedTrace Logo

Tezepelumab Phase 1 PK Study in Healthy Chinese Subjects

NCT04362410 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2020-11-17

No results posted yet for this study

Summary

This is a Phase 1, Single Centre, Double-blind, Randomized, Placebo-controlled Parallel-group Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Tezepelumab after Single-Dose Subcutaneous Administration in Healthy Chinese Subjects.

Conditions

  • Healthy Subjects

Interventions

BIOLOGICAL

Experimental: Tezepelumab

Tezepelumab single dose subcutaneously injection.

OTHER

Placebo

Placebo single dose subcutaneously injection.

Sponsors & Collaborators

Principal Investigators

  • Jinfang Hu, Master · The First Affiliated Hospital of Nanchang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-18
Primary Completion
2020-10-09
Completion
2020-10-09
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04362410 on ClinicalTrials.gov